Key Highlights
- Loss was USD 0.30 per share against an estimated USD 0.94 loss, and Revenue of USD 9.98 million beat estimates.
- Revenue fell from USD 19.07 million a year earlier, but nine-month revenue rose to USD 41.3 million.
- Cash was USD 122.2 million, which the company guided to fund operations into the first quarter of 2028.
- Initial Phase 1 data for XTX501 in metastatic lung cancer are guided for the fourth quarter of 2027.
Xilio Therapeutics (NASDAQ:XLO), a clinical-stage immuno-oncology company, reported a third quarter 2026 loss of USD 0.30 per share, far narrower than the USD 0.94 estimated loss. Revenue of USD 9.98 million, all collaboration and license revenue, compared with the USD 4.92 million estimate but fell from USD 19.07 million in the third quarter of 2025.
For the nine months ended September 30, revenue was USD 41.3 million against USD 30.1 million a year earlier, and net loss was USD 21.9 million against USD 45.4 million. The accumulated Deficit was USD 440.6 million.
Research and development expense was USD 14.8 million in the quarter, compared with USD 14.3 million a year earlier, and USD 49.2 million for the nine months, up from USD 37.9 million. General and administrative expense was USD 6.9 million against USD 6.7 million, and USD 21.5 million for the nine months, down from USD 22.3 million. Total operating expenses were USD 21.7 million, up from USD 21.0 million.
Loss from operations widened to USD 11.7 million from USD 1.9 million as revenue fell. The smaller bottom-line loss versus estimates was helped by non-operating items, including a USD 4.8 million gain from the change in Fair Value of common stock Warrant liabilities in the quarter, compared with a USD 15.3 million charge in the third quarter of 2025.
Cash, Runway and Financing
Cash and cash equivalents were USD 122.2 million at September 30, compared with USD 137.5 million at year end. Based on current operating plans, the company guides that existing cash is sufficient to fund operating expenses and Capital Expenditure requirements into the first quarter of 2028. Deferred revenue was USD 15.4 million in current liabilities and USD 9.9 million in non-current liabilities, down from USD 40.0 million and USD 20.6 million at year end.
Net cash provided by financing activities was USD 40.2 million in the first nine months of 2026, mainly from prefunded warrants sold in a follow-on offering and common stock sold through the at-the-market program. In the same period of 2025, financing provided USD 51.9 million, including a June 2025 follow-on offering and a private Placement of common stock to AbbVie.
Pipeline Updates
The company is evaluating XTX501 as a monotherapy in patients with metastatic non-small cell lung cancer and select advanced solid tumors who previously received anti-PD(L)-1 therapy. The first-in-human, open-label Phase 1/2 trial runs at multiple United States sites, and patient dosing recently began. The company plans to report initial Phase 1 data in metastatic non-small cell lung cancer in the fourth quarter of 2027.
Efarindodekin alfa, a masked IL-12 candidate, is being studied as a monotherapy in an ongoing Phase 2 trial in patients with advanced solid tumors under the company's license agreement with Gilead. The company plans to deliver an option data package to Gilead in the first half of 2027.
Dates and Figures to Follow
The first half of 2027 option data package, further dosing in the XTX501 trial, the pace of revenue recognition from deferred balances and the cash balance relative to the first quarter 2028 runway guidance are the items to follow. Fair value changes on warrant liabilities can move reported net loss from quarter to quarter, so operating loss is a cleaner comparison.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...